However, the substantial expression of Gal-1 in human pancreatic cancer and its demonstrable influence on immune response enhancement, tumor cell proliferation reduction, and tumor stroma modification solidify its position as a prospective therapeutic candidate. This evidence concerns the gene LGALS1 and pancreatic neoplasm.